# Waltz Health

**Type:** Healthcare access platform  
**Domain:** GLP-1 direct-to-employer distribution  
**Status:** Active (as of 2026-01)

## Overview

Waltz Health operates a direct-to-employer (DTE) access program for FDA-approved obesity medications, partnering with Novo Nordisk to bypass traditional PBM intermediation.

## Timeline

- **2026-01-01** — Launched DTE access program for FDA-approved obesity medications in partnership with Novo Nordisk

## Business Model

DTE channel for GLP-1 access, competing with traditional PBM distribution. No enrollment data or market penetration disclosed as of Q1 2026.

## Market Position

Part of the emerging manufacturer-direct distribution strategy alongside Eli Lilly's Employer Connect and 9amHealth's No-Barriers Bundle. Expert consensus characterizes DTE as 'incremental governance shift, not structural PBM displacement.'

## Sources

- HR Brew, December 2025
- PR Newswire, January 2026